World Health Organization Classification of Tumors.Pathology and genetics. Tumors of the nervous system, 2000.
2.
AdalpeK.Discrepancies in diagnoses of neuroepithelial neoplasms.Cancer2000; 88: 2342–2349.
3.
InoY.Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.J Neurosurg2000, 92: 883–900.
4.
GrossmanS.A.The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, objectives, and activities.Cancer Control1998, 5(2): 107–114.
5.
ChangS.M.A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report.Cancer2001, 91: 417–422.
6.
KleinbergL., GrossmanS.A.Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer in newly diagnosed glioblastoma multiforme.J Clin Oncol1999, 17: 2593–2603.
7.
WalkerM.D.Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.J Neurosurg1978, 49: 333–343.
8.
PradosM.D.A phase III randomized study or radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BudR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.Int J Radiat Oncol Biol Phys1999, 45: 1109–1115.
9.
LaperriereN.J.Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.Int J Radiat Oncol Biol Phys1998, 41: 1005–1011.
10.
BradaM.Radiosurgery for brain tumours.BMJ1999, 13: 411–412.
11.
Medical Research Council Brain Tumor Working Party:Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial.J Clin Oncol2001, 19: 509–518.
12.
DeAngelisL.M.Malignant glioma: who benefits from adjuvant chemotherapy?Ann Neurol1998, 44: 691–695.
13.
PradosM.D.Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.J Clin Oncol1999, 17: 3389–3395.
14.
BrandesA.A.Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.J Neurooncol1996, 30: 247–255.
15.
BrandesA.A.Carboplatin and teniposide concurrent with radiotherapy in glioblastoma multiforme: a phase II study.Cancer1998, 82: 355–361.
16.
YungW.K.A.A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.Br J Cancer2000, 83: 588–593.
17.
BrandesA.A.Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.Ann Oncol2001, 12: 255–257.
18.
BrandesA.A.High dose chemotherapy with bone marrow rescue for high grade gliomas in adults.Cancer Invest2001, 19: 41–48.
19.
EstellerM.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.N Engl J Med2000, 343: 1350–1354.
20.
BrandesA.A.Procarbazine prior to and concomitant with BCNU in patients with glioblastoma at first relapse: a phase II study.Proc Am Soc Clin Oncol2001, 20: abs 240.
21.
FriedmanH.S.Temozolomide and treatment of malignant glioma.Clin Cancer Res2000, 6: 2585–2597.
22.
LeeS.M.Inactivation of O6-alkylguanine-DNA-alkyl-transferase in human peripheral blood mononuclear cells by temozolomide.Br J Cancer1994, 69: 452–456.
23.
FigueroaJ.A.Protracted cyclic administration of temozolomide is feasible; a phase I, pharmacokinetic and pharmacodynamic study.Proc Am Soc Clin Oncol2000, 19: abs 868.
24.
TolcherA.W.Persistent and marked inactivation of O6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide.Proc Am Soc Clin Oncol2000, 19: abs 680.
25.
DenisL.J.Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study.Proc Am Soc Clin Oncol2000, 19: abs 786.
26.
SoffiettiR.Prognostic factors in well-differentiated cerebral astrocytomas in the adults.Neurosurgery1989, 24: 686–692.
27.
KarimA.B.A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.Int J Radiat Oncol Biol Phys1996, 36: 549–556.
28.
BucknerJ.C.Phase II trial of procarbazine, CCNU, and vincristine (PCV) as initial therapy in patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy results and associations with chromosome 1p and 19q loss.Proc Am Soc Clin Oncol1999; 18: abs 40.
29.
MasonW.P.Low-grade oligodendroglioma responds to chemotherapy.Neurology1996, 46: 203–207.
30.
FriedmanA.H.Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temozolomide.Am Soc Clin Oncol1999, 19: abs 654.
31.
ViviersL.A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas.Proc Am Soc Clin Oncol2000, 19: abs 648.
32.
De AngelisL.M.Primary CNS lymphoma: combined treatment with radiotherapy and chemotherapy.Neurology1990, 40: 80–86.
33.
NelsonD.F.Non Hodgkin lymphomas of the brain: can high dose, large volume radiation improve survival? Report on a prospective trial by the RTOG.Int J Radiat Oncol1992, 23: 9–17.
HayabuchiN.Primary central nervous system lymphoma in Japan: a nationwide survey.Int J Radiat Oncol Biol Phys1999, 44: 265–272.
42.
FerreriA.J.Therapeutic management of immunocompetent patients with primary central nervous system lymphoma (PCNSL): analysis of an international multicentre series of 378 patients.Blood2000; 96 (11): abs 2186.
43.
ReniM.The clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphoma (PCNSL) treated with upfront high-dose methotrexate (≥ 1g/m2 HD-MTX).Int J Radiat Oncol Biol Phys2000, 48(3, suppl.): abs 255.
44.
RuhstallerT.W.Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma.Ann Oncol2000, 11(3): 374–375.
45.
KrosJ.M.Oligodendroglioma. A comparison of two grading systems.Cancer1988, 52: 2251–2259.
46.
ShawE.G.Oligodendrogliomas: the Mayo Clinic experience.J Neurosurg1992, 76: 428–434.
47.
CairncrossJ.G.Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.J Natl Cancer Inst1998, 90: 1473–1479.
48.
Van den BentM.J.Temozolomide chemotherapy in recurrent oligodendroglioma.Neurology2001, in press.
49.
PackerR.J., PerilongoG.Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma.J Neurosurg1991, 74: 433–440.
50.
BaileyC.C.Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.Med Pediatr Oncol1995, 25: 166–178.
51.
GiangasperoF.Medulloblastoma with extensive nodularity: a variant with favorable prognosis.J Neurosurg1999, 91: 971–977.
52.
SawayaR.Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchimal tumors.Neurosurgery1998, 42: 1044–1056.
ChangS.M.Complications of medical therapy.BernsteinM., BergerM.S. eds. Neuro-oncology: the essentials.Thieme, NY2000, 478–485.
56.
PlanzG.E.T cell adoptive immunotherapy of newly diagnosed gliomas.Clin Cancer Res2000, 6: 2209–2218.
57.
MarkertJ.M.Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene Ther2000, 7: 867–874.
58.
RamplingR.Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.Gene Ther2000, 7: 859–866.
59.
ShandN.A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.Hum Gene Ther1999, 10: 2325–2335.
60.
PalùG.Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.Gene Ther1999, 6: 330–337.
61.
CrinòL.Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project.J Clin Oncol1999, 17: 3522–3530.
62.
BradaM., YungWK.Clinical trial end points in malignant glioma: need for effective trial design strategy.Semin Oncol2000, 27: 11–19.
63.
YungW.K.A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.Br J Cancer2000, 83: 588–593.
64.
FueyoJ.A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Oncogene2000, 19: 2–12.
